New combo therapy trial offers hope for Tough-to-Treat breast cancer
NCT ID NCT03368729
Summary
This study is testing whether adding a pill called niraparib to the standard IV drug trastuzumab is safe and effective for people with advanced HER2-positive breast cancer that has spread. It's for patients whose cancer has grown despite previous HER2-targeted treatments. The main goals are to find the safest dose and see if the combination helps shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Montefiore
The Bronx, New York, 10461, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Washington-
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.